Abdi Ibrahim Ilac San. ve Tic A.S.
10
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
30%
3 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option
Role: collaborator
Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients
Role: lead
Prevalence and Clinical Associates of Iron Deficiency in Patients With Atrial Fibrillation
Role: collaborator
Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions
Role: collaborator
Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions
Role: collaborator
Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis
Role: collaborator
Metabolic Syndrome Prevalence Study
Role: lead
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition
Role: collaborator
Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition
Role: collaborator
Efficacy and Safety Study of Udenafil Tablets in Erectile Dysfunction.
Role: lead
All 10 trials loaded